Molecular and Structural Biomarkers of Inflammation at Two Years After Acute Anterior Cruciate Ligament Injury Do Not Predict Structural Knee Osteoarthritis at Five Years.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 01 2018
accepted: 02 08 2018
pubmed: 7 8 2018
medline: 5 11 2019
entrez: 7 8 2018
Statut: ppublish

Résumé

To determine the role of inflammatory biomarkers at 2 years post-anterior cruciate ligament (ACL) injury to predict radiographic knee osteoarthritis (OA) and magnetic resonance imaging (MRI)-defined knee OA at 5 years postinjury, with a secondary aim of estimating the concordance of inflammatory biomarkers assessed by MRI and synovial fluid (SF) analysis. We studied 113 patients with acute ACL injury. Knee scans using 1.5T MRIs were read for Hoffa- and effusion-synovitis. Biomarkers of inflammation that we assessed included interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor, and interferon-ɣ in serum and SF, and IL-12p70 in serum. We defined the outcome as radiographic knee OA (ROA) or MRI-defined OA (MROA) at 5 years. The area under the receiver operating characteristic curve (AUC), sensitivity, and specificity were evaluated in models that included MRI features only (model 1), inflammation biomarkers only (serum [model 2a] or SF [model 2b]), both MRI features and serum biomarkers (model 3a), or both MRI features and SF (model 3b) biomarkers. Linear regression analysis was used to evaluate the association between MRI features and SF biomarkers. At 5 years postinjury, ROA was present in 26% of the injured knees, and MROA was present in 32%. The AUCs for ROA in each model were 0.44 (95% confidence interval [95% CI] 0.42, 0.47) for model 1, 0.62 (95% CI 0.59, 0.65) for model 2a, 0.53 (95% CI 0.50, 0.56) for model 2b, 0.58 (95% CI 0.55, 0.61) for model 3a, and 0.50 (95% CI 0.46, 0.53) for model 3b. The AUCs for MROA in each model were 0.67 (95% CI 0.64, 0.70) for model 1, 0.49 (95% CI 0.47, 0.52) for model 2a, 0.56 (95% CI 0.52, 0.59) for model 2b, 0.65 (95% CI 0.61, 0.68) for model 3a, and 0.69 (95% CI 0.66, 0.72) for model 3b. The concordance between MRI and SF biomarkers was statistically significant only for effusion-synovitis and IL-8. Neither MRI-detected inflammation nor selected SF/serum inflammation biomarkers at 2 years postinjury predicted ROA or MROA at 5 years postinjury. Concordance between MRI and SF inflammatory biomarkers was weak.

Identifiants

pubmed: 30079991
doi: 10.1002/art.40687
doi:

Substances chimiques

Biomarkers 0
CXCL8 protein, human 0
IFNG protein, human 0
IL10 protein, human 0
IL6 protein, human 0
Interleukin-6 0
Interleukin-8 0
TNF protein, human 0
Tumor Necrosis Factor-alpha 0
Interleukin-10 130068-27-8
Interleukin-12 187348-17-0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

238-243

Subventions

Organisme : Swedish Research Council
Pays : International
Organisme : Swedish National Center for Research in Sports
Pays : International
Organisme : Crafoord Foundation
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2018, American College of Rheumatology.

Auteurs

Frank W Roemer (FW)

University of Erlangen-Nuremberg, Erlangen, Germany, Quantitative Imaging Center and Boston University School of Medicine, Boston, Massachusetts, and Lund University, Lund, Sweden.

Martin Englund (M)

Lund University, Lund, Sweden.

Aleksandra Turkiewicz (A)

Lund University, Lund, Sweden.

André Struglics (A)

Lund University, Lund, Sweden.

Ali Guermazi (A)

Quantitative Imaging Center and Boston University School of Medicine, Boston, Massachusetts.

L Stefan Lohmander (LS)

Lund University, Lund, Sweden.

Staffan Larsson (S)

Lund University, Lund, Sweden.

Richard Frobell (R)

Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH